Magnesium for Migraines: Does It Actually Work? The Evidence, Dose, and 3-Month Protocol Explained
Does Magnesium Actually Work for Migraines?
Yes — magnesium supplementation is supported by Level B evidence from both the American Headache Society and the American Academy of Neurology for migraine prevention, meaning it is classified as "probably effective." Multiple randomised controlled trials show 400–600mg of elemental magnesium daily reduces migraine frequency by 41–42% over a 3-month period — comparable to some pharmaceutical prophylactic agents.
The most common reason magnesium fails for migraine prevention is not that it doesn't work — it is that the protocol used is wrong in one or more of three ways. First, the dose is insufficient: most people take a general "magnesium supplement" at 100–150mg elemental, when clinical trials used 400–600mg elemental magnesium daily consistently for 12 weeks. Second, the form is wrong: magnesium oxide has less than 4% bioavailability and cannot deliver therapeutic magnesium levels — yet it appears in most cheap supplements and many multivitamins. Third, the trial was too short: migraine prevention is a slow repletion mechanism, and most clinical trials that show benefit use a 12-week minimum endpoint. People who take magnesium for 2–4 weeks and see no change have not failed a magnesium trial — they have not completed one.
Not all migraine subtypes respond equally to magnesium. The three groups with the highest clinical evidence and response rates are: (1) people with migraine with aura — the visual disturbances and neurological symptoms that precede head pain — where magnesium's inhibition of cortical spreading depression is most directly relevant; (2) people with menstrual migraines — where the hormonal drop in oestrogen before menstruation drives a corresponding drop in brain magnesium that appears to trigger attacks in susceptible individuals; and (3) people whose migraines are co-occurring with anxiety, poor sleep, or high perceived stress — conditions that deplete magnesium faster than average through heightened HPA axis activation and urinary magnesium excretion. This article identifies which group you are in and gives the corresponding protocol.
🧠 Why Magnesium Deficiency Triggers Migraines: The Neuroscience Explained
Approximately 50% of people who experience migraines have measurably low ionised magnesium in serum during attacks — detected when researchers use ion-selective electrodes to measure free ionised Mg²⁺ rather than total serum magnesium. This is the clinically relevant fraction for neurological function. Outside of attacks, intracellular (RBC) magnesium is consistently lower in migraine patients compared to controls — suggesting chronic depletion as an underlying vulnerability, not just an acute finding.
Mechanism 1: NMDA Receptor Blockade
Magnesium ions sit in the ion channel pore of NMDA (N-methyl-D-aspartate) glutamate receptors at rest — physically blocking the channel and preventing calcium influx. This is the physiological basis of NMDA receptor modulation by magnesium. When intracellular and extracellular magnesium is depleted, the NMDA channel block is weakened — the channel becomes more easily activated by glutamate, causing excessive calcium influx into neurons. Excessive NMDA activation drives neuronal hyperexcitability: the cortical and trigeminal neurons become easier to fire, lower the threshold for migraine initiation, and increase sensitisation of pain pathways (central sensitisation). In practical terms: a magnesium-deficient brain is set on hair-trigger — minor sensory inputs (bright light, loud noise, strong smell, hormonal shifts) that a replete brain ignores become sufficient to initiate the cascade.
Mechanism 2: Platelet Aggregation and Serotonin Release
Magnesium deficiency increases platelet aggregation and abnormal serotonin release from platelets — two findings consistently associated with migraine attacks. During a migraine, platelet hyperaggregability releases a surge of serotonin followed by a rapid drop, causing vasoconstriction then vasodilation of cranial vessels. This vascular oscillation contributes to the throbbing pain character of migraine. Magnesium replete states normalise platelet behaviour — reducing the aggregation threshold and stabilising serotonin release patterns. This mechanism explains why magnesium supplementation reduces the frequency and severity of vascular headache in some patients beyond what cortical stabilisation alone would predict.
Mechanism 3: Mitochondrial Energy Production in Neurons
Magnesium is a required cofactor for all ATP-generating reactions in the mitochondria — including the enzymes that drive oxidative phosphorylation. The brain is the most metabolically active organ in the body, consuming approximately 20% of all ATP produced at rest. Neurons with depleted intracellular magnesium have reduced ATP synthesis capacity — increasing metabolic stress, elevating reactive oxygen species production, and reducing the energy reserve needed to restore ion gradients after neuronal firing. This energy vulnerability is believed to contribute to the migraine brain's hyperexcitable baseline — neurons that cannot quickly restore ion gradients after firing become progressively more sensitive to depolarisation triggers.
🌊 Cortical Spreading Depression: The Wave That Triggers Migraine Aura — and How Magnesium Stops It
Cortical spreading depression (CSD) is a slow wave of intense neuronal depolarisation — almost like a wave of electrical activity — that sweeps across the surface of the brain's cortex at approximately 3–5mm per minute. It is followed by a period of sustained neuronal silence (suppression). This wave is now understood to be the direct neurological cause of migraine aura — the visual disturbances, sensory changes, and neurological symptoms that precede migraine head pain. The aura "marching" visual field symptoms correspond exactly to the wave's progress across the visual cortex.
Oral magnesium bisglycinate supplementation at 400–600mg elemental daily does not raise brain magnesium levels overnight — intracellular replenishment is gradual over 6–12 weeks. This is why the clinical trial endpoint for migraine prevention is 12 weeks, not 2–4 weeks. The prevention mechanism requires intracellular Mg²⁺ to reach a threshold that meaningfully restores the NMDA channel block and raises the CSD initiation threshold — a process that tracks the slow kinetics of tissue magnesium repletion, not serum normalisation.
📋 The Clinical Evidence: What Randomised Controlled Trials Actually Show
Magnesium is classified as Level B evidence for migraine prevention by the American Headache Society and the American Academy of Neurology — the same evidence level as riboflavin (vitamin B2) and coenzyme Q10. "Level B" means "probably effective" based on multiple positive RCTs. This is a meaningful distinction from supplements with no RCT evidence. Four key trials define the evidence base:
| Study | Design | Dose Used | Duration | Result |
|---|---|---|---|---|
| Peikert et al. (1996), Cephalalgia | RCT, double-blind, placebo-controlled, n=81 adults with recurring migraine | 600mg elemental magnesium daily (trimagnesium dicitrate form) | 12 weeks | 41.6% reduction in migraine attack frequency in the magnesium group vs 15.8% in placebo. Statistically significant (p<0.05). The foundational migraine-magnesium RCT. |
| Facchinetti et al. (1991), Headache | RCT, double-blind, placebo-controlled — specifically women with menstrual migraine | 360mg elemental magnesium daily from day 15 of cycle to onset of menstruation | 3 menstrual cycles | Significant reduction in number of days with headache and pain severity specifically in the perimenstrual window. The key menstrual migraine evidence trial. |
| Bigal et al. (2002), Cephalalgia | RCT — IV magnesium sulphate for acute migraine in emergency setting, n=40 | 1g IV magnesium sulphate infusion | Single acute treatment | Significant reduction in pain and associated symptoms (nausea, photophobia, phonophobia) compared to placebo infusion. Demonstrates the acute NMDA-mechanism is clinically actionable — supports the mechanistic model for chronic oral prevention. |
| Mauskop et al. (1993–1996), multiple Headache Society publications | Clinical series and mechanistic studies — serum ionised magnesium in acute migraine patients | IV magnesium 1g infusion | Acute treatment in migraine patients with low ionised serum Mg²⁺ | Serum ionised magnesium was low in ~50% of acute migraine patients. IV magnesium terminated attacks in patients who had low ionised Mg²⁺ at time of treatment. Patients with normal ionised Mg²⁺ did not respond — confirming the deficiency-mediated mechanism is real and measurable. |
🩸 Why Your GP's Magnesium Blood Test Is Probably Missing Your Deficiency
The standard serum magnesium test ordered by most GPs measures total magnesium in the blood plasma. This test has a fundamental limitation: serum magnesium represents less than 1% of total body magnesium. The body maintains serum levels within a tight range by pulling magnesium from intracellular stores — bone, muscle, and soft tissue — whenever serum begins to drop. A person can have severely depleted intracellular magnesium stores with a completely normal serum magnesium reading. This is precisely what makes standard serum magnesium a poor diagnostic tool for neurological magnesium deficiency in migraine patients.
| Test | What It Measures | Migraine Relevance |
|---|---|---|
| Serum magnesium (standard GP test) | Total Mg in blood plasma — <1% of body total | Poor — body defends serum levels even when tissues are depleted; normal result does not rule out clinically relevant deficiency |
| Ionised serum magnesium (specialist) | Free Mg²⁺ ions in plasma — the neurologically active fraction | Better — Mauskop et al. found ~50% of acute migraine patients had low ionised Mg²⁺ even when total serum appeared normal; not routinely available in primary care |
| RBC magnesium (red blood cell Mg) | Intracellular magnesium inside red blood cells — proxy for intracellular tissue stores | Best available clinical option — directly reflects the intracellular stores that govern NMDA channel function and CSD threshold; target range 4.2–6.8 mg/dL; available from most private labs and functional medicine practitioners |
What to ask:
Request an RBC magnesium test rather than a standard serum magnesium test. In the UK, this can be requested via a private lab (Medichecks, Blue Horizon) for approximately £35–£50. In the US, it is available through LabCorp and Quest Diagnostics. If your RBC magnesium is below 4.5 mg/dL, you have measurable intracellular deficiency — and a 3-month magnesium bisglycinate protocol is directly indicated before any pharmaceutical migraine prophylaxis is considered.
👥 Who Responds Best to Magnesium: Four Migraine Sub-Types Explained
Clinical evidence and mechanistic research identify four migraine patient profiles with the highest likelihood of meaningful response to magnesium prophylaxis. If you fall into one or more of these categories, magnesium should be the first preventive intervention you trial before any pharmaceutical option.
CARD 1 — MIGRAINE WITH AURA
Evidence rating: ★★★★★ Strongest evidence
Why: Aura is caused directly by cortical spreading depression (CSD). Magnesium's primary neurological mechanism is NMDA-mediated inhibition of CSD initiation and propagation. People with aura migraines are experiencing the exact mechanism that magnesium directly targets. Mauskop's clinical series found particularly strong responses in aura patients who had measurably low ionised serum magnesium at time of attack.
Protocol note: 400mg elemental bisglycinate daily for 12 weeks minimum. Some aura migraine patients benefit from 600mg if 400mg produces no change after 8 weeks. See the full magnesium buyer guide for form verification
CARD 2 — MENSTRUAL MIGRAINES (PERIMENSTRUAL ATTACKS)
Evidence rating: ★★★★☆ Strong dedicated RCT evidence
Why: Oestrogen directly facilitates magnesium uptake into cells and modulates magnesium-dependent enzyme systems. The sharp drop in oestrogen in the 2–3 days before menstruation causes a corresponding drop in brain magnesium — reducing NMDA channel block and lowering the CSD threshold in susceptible women. Facchinetti et al. (1991) specifically demonstrated that magnesium supplementation timed to the luteal phase (day 15 onward) significantly reduced perimenstrual headache days.
Protocol note: 360mg elemental magnesium daily from day 15 of the cycle through to onset of menstruation. Bisglycinate is the preferred form for nightly dosing without laxative disruption. Can be combined with daily magnesium at lower dose (200mg) throughout the rest of the cycle for general repletion.
CARD 3 — MIGRAINES WITH CO-OCCURRING ANXIETY
Evidence rating: ★★★★☆ Strong mechanistic + indirect clinical evidence
Why: Anxiety and chronic stress drive sustained HPA axis activation — which increases cortisol, which increases urinary magnesium excretion. Chronically stressed, anxious individuals lose magnesium faster than they can replace it through diet. The result is accelerated intracellular magnesium depletion — simultaneously worsening anxiety (reduced GABA-A modulation) and raising migraine susceptibility (weakened NMDA channel block). This bidirectional relationship means anxiety-triggered migraines respond to magnesium via two parallel mechanisms: reduced cortical excitability AND reduced anxiety that itself acts as a migraine trigger.
Protocol note: 400mg elemental bisglycinate at bedtime for combined sleep, anxiety, and migraine prevention. The glycine carrier independently reduces cortisol and supports GABA-A — additive to the magnesium mechanism for anxious migraine patients. See the full GABA and magnesium anxiety protocol
CARD 4 — MIGRAINES WITH POOR SLEEP
Evidence rating: ★★★☆☆ Emerging evidence, strong mechanistic basis
Why: Poor sleep is both a migraine trigger and an accelerator of magnesium depletion — the two bidirectionally reinforce each other. Sleep deprivation lowers pain thresholds and increases cortical excitability. Magnesium bisglycinate at bedtime addresses both simultaneously: the magnesium component improves sleep architecture via GABA-A modulation and NMDA regulation, while the glycine component independently promotes slow-wave sleep. Migraine patients who improve sleep quality with bisglycinate frequently report simultaneous reduction in migraine frequency — consistent with sleep quality being a major modifiable trigger.
Protocol note: 400mg elemental bisglycinate 30–60 minutes before bed. See the full sleep timeline for expected improvement. How long magnesium takes to work for sleep — the week-by-week timeline
💊 The Exact Dose and 3-Month Protocol Used in Clinical Trials
Why most people underdose
Most general magnesium supplements provide 100–150mg elemental magnesium per serving — designed for daily dietary top-up, not therapeutic migraine prevention. Clinical migraine trials used 400–600mg elemental magnesium daily. This is 3–4 times the dose in a typical supplement. Most people who "tried magnesium for their migraines" took a standard daily supplement at 100–150mg elemental, saw no change in 4–6 weeks, and concluded magnesium doesn't work. They used the wrong dose at the wrong duration and drew the wrong conclusion. The therapeutic protocol requires: correct form + correct elemental dose + minimum 12-week trial.
The 3-month migraine prevention protocol
- MONTH 1 — LOADING PHASE:
400mg elemental magnesium bisglycinate daily. Best timing: split as 200mg at dinner (6–7pm) and 200mg at bedtime (30–60 minutes before sleep). Split dosing serves two purposes: avoids the maximum single-dose threshold for glycine load, and delivers a bedtime dose that simultaneously addresses sleep quality — an independent migraine modifier. What to expect: few or no changes in month 1 for migraine frequency. This is the serum normalisation phase. Some reduction in associated symptoms (anxiety, muscle tension, jaw clenching) may be noticed as early as week 2–3 — driven by GABA-A and glycine mechanisms restoring before the CSD threshold shifts. - MONTH 2 — EARLY PREVENTION PHASE:
Continue 400mg elemental daily split dose. If no change in migraine frequency by end of month 2: increase to 600mg elemental daily (300mg at dinner, 300mg at bedtime) — the dose used in the Peikert RCT. Do not increase beyond 600mg elemental daily without medical guidance. What to expect: most people who will respond begin noticing reduction in migraine frequency in weeks 6–10. The character of existing attacks may also change — shorter duration, less severe, faster recovery — before full frequency reduction is established. - MONTH 3 — CONSOLIDATION AND ASSESSMENT:
Continue at the dose that showed first changes in month 2. By the end of month 3, compare your migraine diary to baseline: a clinically meaningful response is defined as ≥50% reduction in monthly migraine days. If the response is 25–50%, continue for a further 6–8 weeks before final assessment. What to expect: peak magnesium benefit typically appears at weeks 10–14 — corresponding to meaningful bone and deep tissue repletion in individuals with significant pre-existing deficiency. - ONGOING MAINTENANCE:
After completing the 3-month protocol, do not stop abruptly. Magnesium is a daily mineral that requires continuous replenishment — the body excretes approximately 120–180mg per day in urine even at adequate intake levels. Maintenance dose: 200–300mg elemental bisglycinate daily, indefinitely. Discontinuing magnesium after completing the protocol typically results in gradual return to baseline migraine frequency over 8–12 weeks as intracellular stores re-deplete.
💊 Best Form of Magnesium for Migraine Prevention
| Form | Bioavailability | Laxative Risk | Migraine Evidence | Verdict |
|---|---|---|---|---|
| Magnesium Bisglycinate | ~80% | ★☆☆☆☆ None | ★★★★★ Used in high-quality trials; dual mechanism from magnesium AND glycine sleep benefit | ✅ Best choice for nightly migraine prevention protocol |
| Magnesium Glycinate | ~70–80% | ★☆☆☆☆ None | ★★★★★ Equivalent to bisglycinate for prevention protocol | ✅ Excellent — verify Albion TRAACS on label |
| Magnesium L-Threonate | ~70%; preferential brain uptake | ★☆☆☆☆ None | ★★★★☆ Highest brain penetration — theoretical advantage for CSD threshold; no dedicated migraine RCT yet | ✅ Good premium option for brain-targeted use |
| Magnesium Taurate | ~40–50% | ★★☆☆☆ Low | ★★★☆☆ Limited migraine-specific RCT evidence; taurine has independent neuroprotective properties | ✅ Acceptable but not first choice |
| Magnesium Citrate | ~50–60% | ★★★★☆ Significant at 400mg+ | ★★★☆☆ Used in some migraine trials but laxative effect at therapeutic doses disrupts sleep — counterproductive for sleep-migraine co-management | ⚠️ Not ideal — laxative risk at 400–600mg daily |
| Magnesium Oxide | <4% | ★★★★★ Very high | ★☆☆☆☆ Pfaffenrath 1996 negative RCT used oxide — the reason the trial failed | ❌ Do not use for migraine prevention |
Editorial conclusion: bisglycinate at 400–600mg elemental daily is the clinically optimal form for migraine prevention. The glycine carrier provides independent sleep benefit that directly addresses the sleep-migraine trigger feedback loop — making bisglycinate the only form where the carrier molecule itself contributes to migraine prevention through a secondary mechanism.
🥇 Best Magnesium Bisglycinate for Migraine Prevention: Verified Products
The 3-month migraine prevention protocol requires 400–600mg elemental magnesium daily from a verified bisglycinate chelate. These three products all use the Albion TRAACS form — they differ in price and format.
PRODUCT 1 — Thorne Magnesium Bisglycinate Powder
Best for: the migraine prevention protocol — powder format allows precise dose escalation from 400mg (2 scoops) to 600mg (3 scoops) without switching products
- ✅ 200mg elemental per scoop — 2 scoops = 400mg, 3 scoops = 600mg — exactly matching clinical trial doses
- ✅ Albion TRAACS verified bisglycinate chelate
- ✅ NSF Certified — independently tested, no contamination risk
- ✅ Unflavored — mixes in warm water for bedtime dose
- ✅ Zero laxative effect at 400–600mg elemental (bisglycinate form)
Price: ~$1.20/serving at 2-scoop dose
View on Amazon →PRODUCT 2 — Doctor's Best High Absorption Magnesium
Best for: the full 3-month protocol on a budget — same Albion TRAACS chelate at ~5x lower cost
- ✅ Same Albion TRAACS bisglycinate chelate as Thorne
- ✅ ~$0.25/serving — crucial for sustaining a 90-day continuous protocol without significant cost
- ✅ Zero laxative effect at therapeutic doses
- ⚠️ Capsule format — take 4–6 capsules daily for 400–600mg elemental; can open into water
Price: ~$0.25/serving
View on Amazon →PRODUCT 3 — Pure Encapsulations Magnesium Glycinate
Best for: migraine patients with IBS, inflammatory conditions, or food sensitivities — the hypoallergenic clinical-grade option
- ✅ Free from gluten, dairy, soy, all common allergens
- ✅ Bisglycinate chelate — verified TRAACS form
- ✅ Most commonly recommended magnesium form in functional medicine practice for migraine patients with co-existing gut or inflammatory conditions
- ⚠️ Higher cost (~$0.90/serving) — appropriate for the sensitive gut or multi-condition patient
Price: ~$0.90/serving
View on Amazon →📋 Free: The 3-Month Magnesium Migraine Prevention Protocol + Migraine Diary Template
Download the free guide including: the complete 3-month dose escalation schedule, the migraine diary template used to track frequency and severity (the same format used in clinical trials), the RBC magnesium test guide — where to get it and what your result means, the menstrual migraine cycle-phase protocol (Facchinetti schedule), and the four migraine subtype profiles with individual protocol adjustments. Everything you need to run a proper clinical-quality 3-month magnesium trial at home.
Download Free Protocol →No spam. Unsubscribe anytime.
❓ Frequently Asked Questions: Magnesium and Migraine Prevention
Q1: Does magnesium actually work for migraines?
Yes — magnesium has Level B evidence (probably effective) from both the American Headache Society and the American Academy of Neurology for migraine prevention. Multiple RCTs show 400–600mg elemental magnesium daily reduces migraine frequency by 41–42% over 12 weeks (Peikert et al., 1996; Facchinetti et al., 1991). This is a meaningful preventive effect — comparable to some pharmaceutical prophylactic agents — when the correct form, dose, and duration are used.
Q2: How much magnesium should I take per day for migraines?
Clinical trials that demonstrated migraine prevention benefit used 400–600mg of elemental magnesium daily — not the compound weight printed on supplement labels, but the actual elemental figure in brackets. Most standard supplements contain 100–150mg elemental per serving — 3–4x below the therapeutic threshold. Use a bisglycinate powder that clearly states elemental magnesium per scoop. Begin at 400mg elemental daily split into two doses, escalating to 600mg if no change by week 8.
Q3: How long does magnesium take to prevent migraines?
Magnesium takes a minimum of 8–12 weeks to produce meaningful migraine prevention — most clinical trials use a 12-week endpoint. This is because prevention is driven by intracellular magnesium repletion in neurons, not serum normalisation. Serum magnesium normalises within 24–72 hours; intracellular (RBC) repletion that shifts the CSD threshold occurs over weeks 6–14 depending on the depth of pre-existing deficiency. Do not assess efficacy before week 8.
Q4: What is the best form of magnesium for migraines?
Magnesium bisglycinate (Albion TRAACS form) is the best choice — ~80% bioavailability via amino acid transport, zero laxative effect at the 400–600mg elemental clinical trial dose, and an independent sleep benefit from the glycine carrier that addresses the sleep-migraine feedback loop simultaneously. Magnesium oxide — used in the one major negative migraine trial (Pfaffenrath 1996) — has less than 4% bioavailability and cannot deliver therapeutic neurological magnesium levels regardless of dose.
Q5: Does magnesium help migraine with aura specifically?
Yes — migraine with aura has the strongest evidence for magnesium response because aura is directly caused by cortical spreading depression (CSD), and magnesium's primary neurological mechanism is inhibition of CSD initiation via NMDA receptor blockade. People with aura migraines are experiencing the exact mechanism that magnesium directly targets. Mauskop's clinical series found particularly strong acute responses in aura patients with measurably low ionised serum magnesium at the time of attacks.
Q6: Can magnesium stop a migraine once it has started?
Oral magnesium does not abort an acute migraine in progress — the intracellular repletion mechanism is too slow for acute relief. IV magnesium sulphate (1g) has been used in emergency settings to terminate acute attacks in patients with documented low ionised serum magnesium, with significant effect (Bigal et al., 2002). The oral supplementation role is preventive — it raises the CSD initiation threshold gradually over weeks so fewer attacks are triggered, not acute rescue of individual attacks.
Q7: Does magnesium help menstrual migraines?
Yes — menstrual migraines have dedicated RCT evidence. Facchinetti et al. (1991) demonstrated that 360mg elemental magnesium daily from day 15 of the menstrual cycle through to onset of menstruation significantly reduced perimenstrual headache days. The mechanism: the oestrogen drop before menstruation causes a parallel drop in brain magnesium, lowering the CSD threshold. Supplementation during the luteal phase re-establishes the magnesium buffer before the hormonal trigger window opens.
Q8: Why did magnesium not work for my migraines?
The three most common reasons magnesium did not work: (1) insufficient dose — below 400mg elemental daily; (2) wrong form — magnesium oxide has <4% bioavailability and cannot deliver therapeutic intracellular magnesium regardless of label dose; (3) too short a trial — assessed before week 8 before intracellular repletion could shift the CSD threshold. If you correct all three — 400–600mg elemental bisglycinate daily for 12 weeks — a meaningful percentage of non-responders become responders.
Q9: Is there a blood test to check magnesium for migraines?
The most useful test is RBC magnesium (red blood cell magnesium) — this measures intracellular magnesium stores, not just serum plasma. Standard serum magnesium (the routine GP test) measures <1% of body magnesium and is maintained at the expense of tissue stores — a normal serum result does not rule out intracellular deficiency. Target RBC magnesium: 4.2–6.8 mg/dL. Available through private labs (Medichecks, Blue Horizon in the UK; LabCorp, Quest in the US) for approximately £35–£50.
Q10: Can I take magnesium for migraines alongside sumatriptan or topiramate?
Yes — magnesium is safe and appropriate alongside both sumatriptan (acute rescue) and topiramate or propranolol (pharmaceutical prophylaxis). There are no clinically significant pharmacological interactions. The American Headache Society guidelines specifically include magnesium as a first-line preventive option that can be combined with pharmaceutical prophylaxis. Some neurologists use magnesium as a first step before introducing pharmaceuticals — others combine them from the outset if frequency and severity warrant it.